210 related articles for article (PubMed ID: 12794752)
1. Endogenous decoy receptor 3 blocks the growth inhibition signals mediated by Fas ligand in human pancreatic adenocarcinoma.
Tsuji S; Hosotani R; Yonehara S; Masui T; Tulachan SS; Nakajima S; Kobayashi H; Koizumi M; Toyoda E; Ito D; Kami K; Mori T; Fujimoto K; Doi R; Imamura M
Int J Cancer; 2003 Aug; 106(1):17-25. PubMed ID: 12794752
[TBL] [Abstract][Full Text] [Related]
2. Fas-mediated apoptosis and expression of related genes in human malignant hematopoietic cells.
Kim KM; Lee K; Hong YS; Park HY
Exp Mol Med; 2000 Dec; 32(4):246-54. PubMed ID: 11190279
[TBL] [Abstract][Full Text] [Related]
3. The prognostic significance of overexpression of the decoy receptor for Fas ligand (DcR3) in patients with gastric carcinomas.
Takahama Y; Yamada Y; Emoto K; Fujimoto H; Takayama T; Ueno M; Uchida H; Hirao S; Mizuno T; Nakajima Y
Gastric Cancer; 2002; 5(2):61-8. PubMed ID: 12111580
[TBL] [Abstract][Full Text] [Related]
4. Human pancreatic adenocarcinomas express Fas and Fas ligand yet are resistant to Fas-mediated apoptosis.
Ungefroren H; Voss M; Jansen M; Roeder C; Henne-Bruns D; Kremer B; Kalthoff H
Cancer Res; 1998 Apr; 58(8):1741-9. PubMed ID: 9563493
[TBL] [Abstract][Full Text] [Related]
5. Human pancreatic cancer cells express non-functional Fas receptors and counterattack lymphocytes by expressing Fas ligand; a potential mechanism for immune escape.
Elnemr A; Ohta T; Yachie A; Kayahara M; Kitagawa H; Ninomiya I; Fushida S; Fujimura T; Nishimura G; Shimizu K; Miwa K
Int J Oncol; 2001 Jan; 18(1):33-9. PubMed ID: 11115536
[TBL] [Abstract][Full Text] [Related]
6. Decoy receptor 3 expression in AsPC-1 human pancreatic adenocarcinoma cells via the phosphatidylinositol 3-kinase-, Akt-, and NF-kappa B-dependent pathway.
Chen PH; Yang CR
J Immunol; 2008 Dec; 181(12):8441-9. PubMed ID: 19050262
[TBL] [Abstract][Full Text] [Related]
7. Decoy receptor 3 suppresses FasL-induced apoptosis via ERK1/2 activation in pancreatic cancer cells.
Zhang Y; Li D; Zhao X; Song S; Zhang L; Zhu D; Wang Z; Chen X; Zhou J
Biochem Biophys Res Commun; 2015 Aug; 463(4):1144-51. PubMed ID: 26102031
[TBL] [Abstract][Full Text] [Related]
8. Decoy receptor 3 expressed in rheumatoid synovial fibroblasts protects the cells against Fas-induced apoptosis.
Hayashi S; Miura Y; Nishiyama T; Mitani M; Tateishi K; Sakai Y; Hashiramoto A; Kurosaka M; Shiozawa S; Doita M
Arthritis Rheum; 2007 Apr; 56(4):1067-75. PubMed ID: 17393415
[TBL] [Abstract][Full Text] [Related]
9. Silencing of decoy receptor 3 (DcR3) expression by siRNA in pancreatic carcinoma cells induces Fas ligand-mediated apoptosis in vitro and in vivo.
Zhou J; Song S; He S; Wang Z; Zhang B; Li D; Zhu D
Int J Mol Med; 2013 Sep; 32(3):653-60. PubMed ID: 23846297
[TBL] [Abstract][Full Text] [Related]
10. Genomic amplification of a decoy receptor for Fas ligand in lung and colon cancer.
Pitti RM; Marsters SA; Lawrence DA; Roy M; Kischkel FC; Dowd P; Huang A; Donahue CJ; Sherwood SW; Baldwin DT; Godowski PJ; Wood WI; Gurney AL; Hillan KJ; Cohen RL; Goddard AD; Botstein D; Ashkenazi A
Nature; 1998 Dec; 396(6712):699-703. PubMed ID: 9872321
[TBL] [Abstract][Full Text] [Related]
11. DcR3 induces cell proliferation through MAPK signaling in chondrocytes of osteoarthritis.
Hayashi S; Nishiyama T; Miura Y; Fujishiro T; Kanzaki N; Hashimoto S; Matsumoto T; Kurosaka M; Kuroda R
Osteoarthritis Cartilage; 2011 Jul; 19(7):903-10. PubMed ID: 21420502
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment with denbinobin and Fas ligand has a synergistic cytotoxic effect in human pancreatic adenocarcinoma BxPC-3 cells.
Yang CR; Guh JH; Teng CM; Chen CC; Chen PH
Br J Pharmacol; 2009 Aug; 157(7):1175-85. PubMed ID: 19466993
[TBL] [Abstract][Full Text] [Related]
13. Frequent gene amplification and overexpression of decoy receptor 3 in glioblastoma.
Arakawa Y; Tachibana O; Hasegawa M; Miyamori T; Yamashita J; Hayashi Y
Acta Neuropathol; 2005 Mar; 109(3):294-8. PubMed ID: 15627206
[TBL] [Abstract][Full Text] [Related]
14. Decoy receptor 3 (DcR3) is proteolytically processed to a metabolic fragment having differential activities against Fas ligand and LIGHT.
Wroblewski VJ; Witcher DR; Becker GW; Davis KA; Dou S; Micanovic R; Newton CM; Noblitt TW; Richardson JM; Song HY; Hale JE
Biochem Pharmacol; 2003 Feb; 65(4):657-67. PubMed ID: 12566095
[TBL] [Abstract][Full Text] [Related]
15. Fas ligand is expressed in normal breast epithelial cells and is frequently up-regulated in breast cancer.
Müllauer L; Mosberger I; Grusch M; Rudas M; Chott A
J Pathol; 2000 Jan; 190(1):20-30. PubMed ID: 10640988
[TBL] [Abstract][Full Text] [Related]
16. Overexpression of decoy receptor 3 in hepatocellular carcinoma and its association with resistance to Fas ligand-mediated apoptosis.
Shen HW; Gao SL; Wu YL; Peng SY
World J Gastroenterol; 2005 Oct; 11(38):5926-30. PubMed ID: 16273601
[TBL] [Abstract][Full Text] [Related]
17. Ascites from epithelial ovarian cancer contain high levels of functional decoy receptor 3 (DcR3) and is associated with platinum resistance.
Connor JP; Felder M
Gynecol Oncol; 2008 Nov; 111(2):330-5. PubMed ID: 18723214
[TBL] [Abstract][Full Text] [Related]
18. Dcr3 inhibit p53-dependent apoptosis in gamma-irradiated lung cancer cells.
Sung HY; Wu HG; Ahn JH; Park WY
Int J Radiat Biol; 2010 Sep; 86(9):780-90. PubMed ID: 20597837
[TBL] [Abstract][Full Text] [Related]
19. Attenuation of Th1 response in decoy receptor 3 transgenic mice.
Hsu TL; Wu YY; Chang YC; Yang CY; Lai MZ; Su WB; Hsieh SL
J Immunol; 2005 Oct; 175(8):5135-45. PubMed ID: 16210617
[TBL] [Abstract][Full Text] [Related]
20. Correlation between expression of DcR3 on tumor cells and sensitivity to FasL.
Li W; Zhang C; Chen C; Zhuang G
Cell Mol Immunol; 2007 Dec; 4(6):455-60. PubMed ID: 18163957
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
